The immune checkpoint TIGIT, which is highly expressed on T and NK cells in NHL, was targeted in a phase Ia/Ib trial (NCT04045028) evaluating Tiragolumab, either alone or in combination with rituximab, for relapsed/refractory NHL. The gene discussed is TIGIT; the disease is non-Hodgkin lymphoma.